Abstract
Non‐small cell lung cancer (NSCLC) is the most prevalent type of lung cancer. The abnormal expression of many long non‐coding RNAs (lncRNAs) has been reported involved in the progression of various tumours, which can be used as diagnostic indicators or antitumour targets. Here, we found that the long non‐coding RNA 00312 was down‐regulated in paired NSCLC tissues and correlated with poor clinical outcome; decreased linc00312 expression in NSCLC was associated with larger and later stage tumours. Functional experiments showed that linc00312 could inhibit cell proliferation and promote apoptosis in vitro and in vivo. Furthermore, we found that HOXA5 could bind in the promoter of linc00312 and up‐regulated the expression of it. Moreover, linc00312 was down‐regulated in the plasma of NSCLC patients compared with that of healthy volunteers or other pulmonary diseases patients. Taken together, our findings indicated that linc00312 could be a novel diagnosis biomarker and a promising therapeutic target for NSCLC.
Highlights
The cells were diluted with the binding buffer and staining with FITC-Annexin V (AV) and propidium iodide (PI) and analysed with a flow cytometry (FACScanâ; BD Biosciences, San Jose, CA, USA) equipped with the CellQuest software (BD Biosciences)
Even though emerging roles of long non-coding RNAs (lncRNAs) in Non-small cell lung cancer (NSCLC) have been highlighted [21,22,23,24], lung cancer-related lncRNAs are still an emerging field compared to the vast majority of lncRNAs in the human genome and further characterization of these lung cancer-associated lncRNAs will provide a better understanding of their potential roles as biomarker or therapeutic targets
We discovered that the lincRNA00312 was down-regulated in NSCLC tumours compared to the adjacent normal lung tissues, which was consistent with the previous study [18] and confirmed the analysis of the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data sets
Summary
Lung cancer is the most frequently diagnosed cancer and remains the number one cancer-related cause of death in China and worldwide, which is one of the heaviest cancer burdens [1, 2]. Even though we have made great progress in the therapies of lung cancer, the overall 5-year survival rate of the disease is less than 15% [4] It remains a priority of exploring the early detection and treatment targets for NSCLC. Accumulating studies have demonstrated that lncRNAs are emerging as key regulators involved in various biological processes [5,6,7] and a broad range of diseases [8, 9]. According to their location with respect to the nearest protein-coding transcripts, lncRNAs can be categorized as genic or intergenic lncRNAs [10]. We previously showed that GAS5 (growth arrest-specific transcript 5) was down-regulated in NSCLC and increased tumour cell growth arrest and induced a 2017 The Authors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
